TBL-1 and Wnt signaling in pediatric B- and T-cell ALL
Official title: The role of TBL-1 in acute lymphoblastic leukemia
Funded at Children's Hospital of Los Angeles · NIH-11451103 · Data updated 2026-11-12
A project explores whether blocking TBL-1 can make pediatric B- and T-cell acute lymphoblastic leukemia easier to treat, especially after relapse.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hospital of Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $609,010 |
| NIH project number | 1R01CA305140-01A1 |
| Project ID | NIH-11451103 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pediatric patients with B-ALL or T-ALL or potential future trials related to these conditions could benefit from the insights and therapies developed.
✕Less likely to help
Patients without B-ALL or T-ALL or those not suitable for preclinical optimization may see limited direct benefit.
What this research studies
This research focuses on pediatric B-ALL and T-ALL where relapse is common and cures are limited. It studies how TBL-1 helps leukemia cells survive and resist drugs through the Wnt/β-catenin pathway, and tests a potential therapy that disrupts TBL1-β-catenin interactions. The team will use mouse models with an intact immune system and realistic tumor environments to understand intrinsic leukemia mechanisms and how the microenvironment affects drug response. They will evaluate how Tegavivint improves chemosensitivity and optimize its use in preclinical settings. The project aims to translate these findings into strategies that could enhance responses to standard chemotherapy for children with ALL.
Why it matters
Potential benefit: If successful, this work could lead to new therapy options that overcome drug resistance and improve outcomes for children with relapsed ALL.
How similar studies have gone: Previous studies have linked Wnt signaling and TBL1 to leukemia biology, but this project explores a novel therapeutic angle in pediatric ALL with preclinical models.
Where this research is happening
-
Children's Hospital of Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Kim, Yong-Mi — Children's Hospital of Los Angeles
- Study coordinator: Kim, Yong-Mi
Related research
Other NIH-funded projects on the same topics.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
-
Combinatorial targeting for high-risk B-cell ALL treatment
A research effort at West Virginia University is exploring a combination therapy for adult B-cell acute lymphoblastic leukemia using targeted gene silencing and a small-molecule compound to improve treatment in patients.
-
Understanding why Latino children have a higher risk of childhood ALL
This project looks at why Latino children are more likely to develop acute lymphoblastic leukemia and whether genetic ancestry plays a role, with the goal of improving prevention and outcomes.
-
Targeting obesity to improve survival for children with ALL
A new approach explores whether reducing obesity-related factors can make chemotherapy work better for kids with acute lymphoblastic leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.